budesonide + mesalazine

Budesonide + mesalazine is a combination therapy used primarily for the treatment of mild to moderate ulcerative colitis, particularly in patients who are refractory to monotherapy with mesalazine. Budesonide is a synthetic corticosteroid that acts locally in the gastrointestinal tract to reduce inflammation by binding to glucocorticoid receptors and modulating gene expression, thereby suppressing pro-inflammatory cytokines and mediators[1][3][4]. Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an aminosalicylate anti-inflammatory agent that works mainly topically within the colon by inhibiting prostaglandin and leukotriene synthesis, reducing leukocyte migration, and scavenging free radicals[8]. The combination aims to leverage both local steroidal and non-steroidal anti-inflammatory effects for improved control of inflammatory bowel disease activity.